Stephen L. Gwaltney

2.0k citations

25 papers · 1.3k indexed · h-index 17

Organic Chemistry top 5%
Molecular Biology
Oncology top 10%
Endocrinology, Diabetes and Metabolism top 5%
Cellular and Molecular Neuroscience top 10%

Co-authors: William Roush Elizabeth Hansell R.J. Skene Lihong Shi Zhiyuan Zhang Rongda Xu Daniel B. Kassel Michael B. Wallace
Topics: Peptidase Inhibition and Analysis (7 papers)Diabetes Treatment and Management (6 papers)Neuropeptides and Animal Physiology (6 papers)
Cited by: Endocrinology, Diabetes and Metabolism Organic Chemistry Oncology
Journals: Journal of the American Chemical Society Cancer Research Journal of Medicinal Chemistry
Partner nations: United States United Kingdom Japan

In The Last Decade

Stephen L. Gwaltney

25 papers receiving 1.2k citations

Peers

Countries citing papers authored by Stephen L. Gwaltney

Since Specialization

Citations

This map shows the geographic impact of Stephen L. Gwaltney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen L. Gwaltney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen L. Gwaltney more than expected).

Fields of papers citing papers by Stephen L. Gwaltney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen L. Gwaltney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen L. Gwaltney. The network helps show where Stephen L. Gwaltney may publish in the future.

Co-authorship network of co-authors of Stephen L. Gwaltney

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen L. Gwaltney. A scholar is included among the top collaborators of Stephen L. Gwaltney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen L. Gwaltney. Stephen L. Gwaltney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting YAP/TAZ-TEAD signaling as a therapeutic approach in head and neck squamous cell carcinoma 2025 ·Cancer Letters ·Kuniaki Sato,Farhoud Faraji,Rodolfo Daniel Cervantes‐Villagrana,Xingyu Wu,Keiichi Koshizuka,Tomohiko Ishikawa,Ramiro Iglesias‐Bartolomé,Lei Chen,Paula L. Miliani de Marval,Stephen L. Gwaltney,Benjamin A. Adler,J. Silvio Gutkind	6
2	39 (PB027): TEAD inhibition by SW-682 potentiates activity of targeted therapies in NSCLC models 2024 ·European Journal of Cancer ·(unknown),Veronica Jové,(unknown),Robert DuBose,Sandeep Saha,Mark P. Johnson,Sungwoo Ahn,Kristen Gilmore Powell,(unknown),Brian G. Lawhorn,Stephen L. Gwaltney,Wei Shao,Timothy A. Lin	1
3	234 (PB222): Rational combination of pan-TEAD inhibitor SW-682 and MEK inhibitor mirdametinib in head and neck squamous cell carcinomas leads to synergistic response 2024 ·European Journal of Cancer ·(unknown),Lei Chen,Luigi Celentano,(unknown),Veronica Jové,Robert DuBose,Supriya K. Saha,Mark P. Johnson,Brian G. Lawhorn,Stephen L. Gwaltney,Timothy A. Lin,(unknown)	1
4	Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators 2017 ·Bioorganic & Medicinal Chemistry Letters ·Zacharia S. Cheruvallath,Stephen L. Gwaltney,M. Sabat,(unknown),Haixia Wang,Andy Jennings,David J. Hosfield,Bumsup Lee,Yiqin Wu,(unknown),Charles E. Grimshaw	15
5	Design, synthesis and SAR of novel glucokinase activators 2013 ·Bioorganic & Medicinal Chemistry Letters ·Zacharia S. Cheruvallath,Stephen L. Gwaltney,M. Sabat,(unknown),Jun Feng,Haixia Wang,(unknown),(unknown),Andy Jennings,David J. Hosfield,Bumsup Lee,Yiqin Wu	27
6	Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Zhiyuan Zhang,(unknown),R.J. Skene,Lihong Shi,Stephen L. Gwaltney	21
7	Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Michael B. Wallace,Jun Feng,Zhiyuan Zhang,R.J. Skene,Lihong Shi,(unknown),Daniel B. Kassel,Rongda Xu,Stephen L. Gwaltney	50
8	Medicinal Chemistry Approaches to the Inhibition of Dipeptidyl Peptidase IV 2008 ·Current Topics in Medicinal Chemistry ·Stephen L. Gwaltney	22
9	Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors 2007 ·Bioorganic & Medicinal Chemistry ·Yunsong Tong,Akiyo Claiborne,Kent D. Stewart,Chang Park,Peter Kovar,Zehan Chen,R.B. Credo,Wen‐Zhen Gu,Stephen L. Gwaltney,Russell A. Judge,Haiying Zhang,Saul H. Rosenberg,Hing L. Sham,Thomas J. Sowin,Nan‐Horng Lin	33
10	Discovery of Alogliptin: A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV 2007 ·Journal of Medicinal Chemistry ·Jun Feng,Zhiyuan Zhang,Michael B. Wallace,Jeffrey A. Stafford,Stephen W. Kaldor,Daniel B. Kassel,Marc Navre,Lihong Shi,R.J. Skene,Tomoko Asakawa,Koji Takeuchi,Rongda Xu,David R. Webb,Stephen L. Gwaltney	326
11	Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors 2006 ·Bioorganic & Medicinal Chemistry Letters ·Gaoquan Li,Lisa Hasvold,Zhi‐Fu Tao,Gary T. Wang,Stephen L. Gwaltney,(unknown),Peter Kovar,R.B. Credo,Zehan Chen,Haiying Zhang,Chang Park,Hing L. Sham,Thomas J. Sowin,Saul H. Rosenberg,Nan‐Horng Lin	29
12	Synthesis and activity of 1-aryl-1′-imidazolyl methyl ethers as non-thiol farnesyltransferase inhibitors 2004 ·Bioorganic & Medicinal Chemistry Letters ·Qun Li,Gary T. Wang,Tongmei Li,Stephen L. Gwaltney,Keith W. Woods,Akiyo Claiborne,Xilu Wang,(unknown),Jerry D. Cohen,Vincent S. Stoll,Charles W. Hutchins,David J. Frost,Saul H. Rosenberg,Hing L. Sham	10
13	Pyridone-Containing farnesyltransferase inhibitors: synthesis and biological evaluation 2003 ·Bioorganic & Medicinal Chemistry Letters ·Lisa Hasvold,Weibo Wang,Stephen L. Gwaltney,Todd W. Rockway,Lissa T.J. Nelson,Robert A. Mantei,Stephen A. Fakhoury,Gerard M. Sullivan,Qun Li,Nan‐Horng Lin,(unknown),Haiying Zhang,Jerome Cohen,Wen‐Zhen Gu,Kennan C. Marsh,Joy Bauch,Saul H. Rosenberg,Hing L. Sham	64
14	Stereoselective synthesis of an advanced taxusin intermediate: an application of the type 2 intramolecular Diels–Alder reaction 2003 ·Tetrahedron Letters ·Markian M. Stec,Stephen L. Gwaltney,(unknown),Ha Nguyen,Kenneth J. Shea	2
15	Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense 2001 ·Molecular and Biochemical Parasitology ·Conor R. Caffrey,Elizabeth Hansell,Kimberley D. Lucas,Linda S. Brinen,(unknown),(unknown),Stephen L. Gwaltney,William Roush,York‐Dieter Stierhof,Matthew Bogyo,Dietmar Steverding,James H. McKerrow	150
16	Novel sulfonate Derivatives: potent antimitotic agents 2001 ·Bioorganic & Medicinal Chemistry Letters ·Stephen L. Gwaltney,(unknown),Qun Li,Laura Gehrke,R.B. Credo,Robert B. Warner,(unknown),Peter Kovar,David J. Frost,Shi-Chung Ng,Hing L. Sham	18
17	Novel sulfonate analogues of combretastatin A-4 2001 ·Bioorganic & Medicinal Chemistry Letters ·Stephen L. Gwaltney,(unknown),Kenneth J. Barr,Qun Li,Laura Gehrke,R.B. Credo,Robert B. Warner,(unknown),Peter Kovar,Jieyi Wang,(unknown),N A Zielinski,David J. Frost,Shi-Chung Ng,Hing L. Sham	49
18	Vinyl Sulfonate Esters and Vinyl Sulfonamides: Potent, Irreversible Inhibitors of Cysteine Proteases 1998 ·Journal of the American Chemical Society ·William Roush,Stephen L. Gwaltney,Jianming Cheng,Karl A. Scheidt,James H. McKerrow,Elizabeth Hansell	193
19	Bridged to fused ring interchange. The total synthesis of (±)-ledol 1996 ·Tetrahedron Letters ·Stephen L. Gwaltney,Kenneth J. Shea	20
20	Bridged to Fused Ring Interchange. Methodology for the Construction of Fused Cycloheptanes and Cyclooctanes. Total Syntheses of Ledol, Ledene, and Compressanolide 1996 ·The Journal of Organic Chemistry ·Stephen L. Gwaltney,(unknown),Kenneth J. Shea	47

About Stephen L. Gwaltney

Stephen L. Gwaltney is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism and Cellular and Molecular Neuroscience, having authored 25 papers that have together received 1.3k indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (7 papers), Diabetes Treatment and Management (6 papers) and Neuropeptides and Animal Physiology (6 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (350 citations), Organic Chemistry (540 citations) and Oncology (391 citations). Stephen L. Gwaltney has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include William Roush, Elizabeth Hansell, R.J. Skene, Lihong Shi, Zhiyuan Zhang, Rongda Xu, Daniel B. Kassel, Michael B. Wallace, Karl A. Scheidt and James H. McKerrow. Their work appears in journals such as Journal of the American Chemical Society, Cancer Research and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact